In a phase-2 trial on patients with non-alcoholic steatohepatitis, inhibition of caspase-1, − 8 and − 9 using the GS-9450 compound significantly improved liver function [41]. This evidence concerns the gene CASP1 and metabolic dysfunction-associated steatohepatitis.